Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting an upgrade in its Mojo Grade from Sell to Hold as of 18 Aug 2026. Despite a modest day gain of 1.20%, the stock’s technical indicators present a nuanced picture, reflecting both bullish and bearish signals across different timeframes.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 August 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 10 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading from a Sell to a Hold rating with a Mojo Score of 57.0. Despite a recent day decline of 4.81%, the stock’s technical indicators signal a bullish trend, suggesting potential for recovery and growth in the near term.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical parameters, reflecting a nuanced price momentum change. The stock’s recent 5.46% day gain to ₹453.10, coupled with a technical grade upgrade from Sell to Hold, signals evolving market sentiment amid mixed indicator readings.

While the Sensex declined 0.55% on 08 Sep 2026, Gujarat Themis Biosyn Ltd surged 8.93%, marking a standout session in the Pharmaceuticals & Biotechnology sector with a 6.38 percentage-point outperformance. This sharp intraday gain rewrites the short-term narrative for the stock, which has now touched an intraday high of Rs 457.45, just 4.81% shy of its 52-week peak.

Gujarat Themis Biosyn Ltd (stock ID: 925632) has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish stance. This change is underpinned by positive signals from key technical indicators such as MACD, Bollinger Bands, and moving averages, signalling renewed investor interest in this small-cap pharmaceutical and biotechnology player.

While the Sensex declined 0.54% on 07 Sep 2026, Gujarat Themis Biosyn Ltd surged 7.03%, touching an intraday high of Rs 441.85. This 5.73 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally in a broadly weak market environment.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 August 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 August 2026, providing investors with an up-to-date perspective on the company’s standing.

Gujarat Themis Biosyn Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial metrics despite recent quarterly setbacks. The company’s evolving technical trend, solid management efficiency, and consistent returns have contributed to this reassessment, although valuation concerns and certain operational challenges temper enthusiasm.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive directional change, key technical indicators present a mixed picture, reflecting cautious optimism among traders and investors.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 August 2026. The revision reflects a combination of deteriorating technical indicators, expensive valuation metrics, subdued financial trends, and a sideways technical outlook, signalling caution for investors amid challenging market conditions.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with several key indicators signalling a transition from mildly bullish to sideways or bearish trends. The stock’s recent downgrade from a Hold to a Sell rating by MarketsMOJO reflects growing concerns over its near-term price trajectory amid weakening momentum and mixed technical signals.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 8 August 2026. This change reflects a nuanced shift in the company’s technical outlook amid mixed financial performance and valuation concerns, prompting a reassessment of its medium-term prospects.

Gujarat Themis Biosyn Ltd has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on daily moving averages, despite mixed signals from key technical indicators such as MACD, RSI, and Bollinger Bands. This nuanced change comes amid a challenging market backdrop where the stock continues to underperform the Sensex on short-term returns, yet boasts impressive long-term gains.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 August 2026. This shift reflects deteriorating technical indicators, subdued financial trends, expensive valuation metrics, and a decline in overall quality scores, signalling caution for investors amid challenging market conditions.